glp 1 triglycerides Glucagon-like peptide in health and disease GLP-1 and GIP in Type

11.6 Evidence-Based Position Based on current literature: GLP-1 receptor agonists do not inherently cause universal nutrient depletion Intake-related vulnerability is plausible and patient-dependent Long-term micronutrient data remain limited Risk increases with magnitude and duration of weight loss Structured dietary strategy is protective Weight loss pharmacotherapy should be paired with nutritional planning

GLP-1 drugs work by mimicking the hormone and keeping it around longer, which can aid in appetite suppression

( Epub 2014 Jun 19

[19] [20] Whilst some evidence supports probiotic use for specific conditionssuch as antibiotic-associated diarrhoea or certain types of irritable bowel syndromethe quality and strength of evidence varies considerably between different strains and formulations

In 2021, the FDA approved Novo Nordisk's Wegovy, a slight reformulation of Ozempic designed specifically for weight loss, which drove a huge spike in public awareness of GLP-1 agonists